Endocrine Abstracts (2007) 14 P414

CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulphate level and bone mineral density in postmenopausal women

Gábor Speer, Krisztián Bácsi, János P. Kósa & Péter Lakatos

Semmelweis University 1st. Department of Medicine, Budapest, Hungary.

Objective: The CYP3A7 enzyme metabolizes some steroid hormones including dehydroepiandrosterone sulphate (DHEAS). Its expression silenced after birth. Previous study has shown that in case of CYP3A7*1C polymorphism, CYP3A7 enzyme activity persisted a higher level, resulting lower levels of DHEAS in men. The age-related decline of serum DHEAS levels is believed to contribute to osteoporosis. We hypothesized that CYP3A7*1C contribute bone loss through decreased level of serum DHEAS in postmenopausal women.

Patients and methods: 319 postmenopausal women were admitted to study and divided into two subgroups: 217 women with osteoporosis and 102 aged-matched women, without osteoporosis. The CYP3A7*1C polymorphism was genotyped. Serum DHEAS levels and bone mineral density (BMD) were measured.

Results: Homozygous CYP3A7*1C carriers had significantly lower BMD at lumbar spine than that of wild type (T-score with CYP3A7*1C mutant type: −3.27±1.02, T-score with wild type: −1.35±1.53, P=0.041), after a correction of age and DHEAS levels. We did not find significant association between CYP3A7*1C variant and serum DHEAS level in postmenopausal women. Serum DHEAS levels correlated positively with BMD at both lumbar spine (P<0.005) and at femoral neck (P<0.005) in the whole study population.

Conclusion: We have shown the CYP3A7*1C may be associated with decreased bone mass at the lumbar spine independently of serum DHEAS concentrations. This finding and the lack of association between CYP3A7*1C polymorphism and serum DHEAS level in women support the hypothesis that this genetic variation might lead to reduced bone mass through other CYP3A7 hormonal substrates, than DHEAS.

Article tools

My recent searches

No recent searches.